Cover Image
市場調查報告書

癲癇: 開發平台分析

Epilepsy - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232793
出版日期 內容資訊 英文 382 Pages
訂單完成後即時交付
價格
Back to Top
癲癇: 開發平台分析 Epilepsy - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 382 Pages
簡介

癲癇,特徵是由於腦的神經細胞的集合而產生異常信號傳達的神經病變,引起發作。這個障礙,感覺會突然消失,短時間沒有意識,出現痙攣。癲癇的主要原因,是出生時低氧,生產時或青年時期的事故造成頭部受傷,腦瘤,結節性硬化症等與腦損傷造成的遺傳基因Disease,腦膜炎和腦炎等感染疾病,中風和其他腦功能障礙等。主要的症侯,是重複發作,及四肢無力感,焦慮,意識喪失,肌肉的收縮或痙攣等。

本報告提供癲癇的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍
  • 癲癇概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Acorda Therapeutics, Inc.
  • Adamas Pharmaceuticals, Inc.
  • Advicenne Pharma
  • Aeolus Pharmaceuticals, Inc.
  • Aequus Pharmaceuticals Inc.
  • Aestus Therapeutics, Inc.
  • Alexza Pharmaceuticals, Inc.
  • Anavex Life Sciences Corp.
  • Asklepios BioPharmaceutical, Inc.
  • Astellas Pharma Inc.
  • Bial - Portela & Ca, S.A.
  • BioCrea GmbH
  • Biogen, Inc.
  • Bionomics Limited
  • Biovista Inc.
  • Biscayne Pharmaceuticals, Inc.
  • Catalyst Pharmaceutical Partners, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • D-Pharm Ltd.
  • Eisai
  • Grifols, S.A.
  • GW Pharmaceuticals Plc
  • H. Lundbeck A/S
  • Hyundai Pharmaceutical Co., Ltd.
  • INSYS Therapeutics, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Iproteos S.L.
  • Johnson & Johnson
  • Knopp Biosciences LLC
  • Lipicard Technologies Limited
  • Marathon Pharmaceuticals, LLC
  • Marinus Pharmaceuticals, Inc.
  • MedGenesis Therapeutix Inc.
  • Nemus Bioscience, Inc.
  • Neurelis, Inc.
  • Neurocrine Biosciences, Inc.
  • Neuron Biopharma SA
  • Novartis AG
  • OPKO Health, Inc.
  • Pfizer Inc.
  • PharmatrophiX, Inc.
  • Promius Pharma, LLC
  • PTC Therapeutics, Inc.
  • Retrophin Inc.
  • RODES Inc.
  • Sage Therapeutics, Inc.
  • Saniona AB
  • SciFluor Life Sciences, LLC
  • SK Biopharmaceuticals Co., Ltd.
  • 大日本住友製藥
  • 武田藥品工業
  • Trillium Therapeutics Inc.
  • Turing Pharmaceuticals AG
  • UCB S.A.
  • Ultragenyx Pharmaceutical Inc.
  • Upsher-Smith Laboratories, Inc.
  • Vichem Chemie Research Ltd.
  • VistaGen Therapeutics , Inc.
  • Xenon Pharmaceuticals Inc.
  • XERIS Pharmaceuticals, Inc.
  • Zogenix, Inc.
  • Zynerba Pharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 2-DG
  • ADS-4101
  • ADV-6208
  • ADV-6770
  • AEOL-1114B
  • AEOL-11203
  • AEOL-11207
  • arupurazoramu
  • AMPX-0079
  • ANAVEX-273
  • ataluren
  • AV-101
  • AVL-5189
  • BIS-001
  • BNP-TLE
  • BPS-015 SR
  • buribarasetamu
  • BVA-601
  • 大麻二酚
  • 卡馬西平
  • CCG-63802
  • 中樞神經系統障礙用細胞療法
  • CHEC-9
  • CKD-903
  • clobazam
  • CNV-1061436
  • cosyntropin
  • CPP-115
  • CUR-1916
  • Diazepam
  • DP-VPA
  • 癲癇治療藥
  • 癲癇、行動障礙用MAPK抑制劑
  • Epidiolex
  • eslicarbazepine acetate
  • Everolimus
  • fenfluramine hydrochloride
  • fosphenytoin sodium
  • ganaxolone
  • 癲癇用神經肽 Y 受體 Y2、Y5活性遺傳基因療法
  • GWP-42006
  • 組織胺二鹽酸鹽
  • 人類免疫球蛋白
  • INV-170
  • IPR-131
  • IPR-96
  • IPRO-003
  • JNJ-40411813
  • KM-113
  • KM-314
  • lacosamide
  • lamotrigine
  • levetiracetam
  • liatermin
  • LM22A-4
  • lorazepam
  • LSPGR-1
  • LT-4121
  • LT-4122
  • LT-4123
  • LT-4124
  • LT-4125
  • LT-4126
  • magnesium valproate hydrate
  • MB-003
  • midazolam hydrochloride
  • MP-101
  • MRS-5474
  • naluzotan hydrochloride
  • NB-23R1
  • NGT-168
  • NH-34
  • NRP-2945
  • NST-0037
  • NST-0076
  • Dravet症候群用寡核苷酸
  • perampanel
  • Pregabalin
  • propofol hemisuccinate
  • SAGE-217
  • SAGE-689
  • SCT-66
  • selurampanel
  • sepranolone
  • SF-0034
  • SGE-872
  • 辛伐他汀(simvastatin)
  • 癌症性疼痛、癲癇用鈉流通管道阻斷劑 1
  • 癲癇用小分子 2
  • 癌症性疼痛、癲癇用鈉流通管道阻斷劑 2
  • 癲癇用小分子 3
  • 鈉流通管道阻斷劑 癌症性疼痛、癲癇用小分子 3
  • 癲癇用小分子 4
  • 癲癇用小分子
  • 中風、癲癇用小分子
  • 癲癇、疼痛用 Activate Kv7.2/Kv7.3通道活化劑
  • 癲癇用 GABAA受體次單元α-4/γ促效劑
  • 神經疾病用 mGluR5/mGluR6拮抗劑
  • Dravet症候群用 Nav1.6阻斷劑
  • 偏頭痛、癲癇重積症用 GABA 轉氨酶抑制劑
  • 癲癇用小分子 1
  • 癲癇用小分子 2
  • 癲癇用小分子 3
  • 癲癇用小分子 4
  • 中樞神經系統障礙用小分子
  • 癲癇用小分子
  • 發作用小分子
  • 中樞神經用 GABAA受體活化劑/NMDA受體拮抗劑
  • 神經病變痛、癲癇、耳鳴用 Kv7活化劑
  • 中樞神經、代謝障礙耳鼻喉科的病期用 TrkB受體活化劑
  • 癲癇用GABA-A 受體激動劑
  • 癲癇、自閉症用 GABAA-Beta 2受體激動劑
  • 中樞神經系統障礙用 TLR-4拮抗劑
  • 癲癇、腫瘤學用Dynamin抑制劑
  • 腸漏症候群用電位開口型鈉流通管道抑制劑
  • sulthiame
  • TAK-935
  • TF-0081
  • TG-4155
  • topiramate
  • TRP-001
  • TUR-004
  • TUR-005
  • UCB-0942
  • UX-007
  • VAD-1
  • VAD-2
  • VB-3323
  • VID-45110
  • VU-0456810
  • YKP-3089
  • Z-944
  • ZYN-002
  • ■最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9057IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H1 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epilepsy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 11, 15, 17, 2, 71, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 2 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Epilepsy - Overview
  • Epilepsy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Epilepsy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Epilepsy - Companies Involved in Therapeutics Development
    • Adamas Pharmaceuticals Inc
    • Advicenne SA
    • Aeolus Pharmaceuticals Inc
    • Aequus Pharmaceuticals Inc
    • Alexza Pharmaceuticals Inc
    • Anavex Life Sciences Corp
    • Asklepios BioPharmaceutical Inc
    • Astellas Pharma Inc
    • Bial - Portela & Ca SA
    • BioCrea GmbH
    • BioHealthonomics Inc
    • Bionomics Ltd
    • Biovista Inc
    • Biscayne Pharmaceuticals Inc
    • Catalyst Pharmaceuticals Inc
    • Cerecor Inc
    • D-Pharm Ltd
    • Eisai Co Ltd
    • Glialogix Inc
    • Grifols SA
    • GW Pharmaceuticals Plc
    • Hyundai Pharmaceutical Co Ltd
    • INSYS Therapeutics Inc
    • INVENT Pharmaceuticals Inc
    • Iproteos SL
    • Johnson & Johnson
    • Knopp Biosciences LLC
    • Lead Discovery Center GmbH
    • Lipicard Technologies Ltd
    • Lotus Pharmaceutical Co Ltd
    • Marathon Pharmaceuticals LLC
    • Marinus Pharmaceuticals Inc
    • Medicure Inc
    • Mitochon Pharmaceuticals Inc
    • Monosol Rx LLC
    • Neurelis Inc
    • Neurocrine Biosciences Inc
    • NeuroCycle Therapeutics GmbH
    • Neuron Biopharma SA
    • Novartis AG
    • OPKO Health Inc
    • Ovid Therapeutics Inc
    • Pfizer Inc
    • PharmatrophiX Inc
    • Promius Pharma LLC
    • Proximagen Ltd
    • PTC Therapeutics Inc
    • Retrophin Inc
    • Sage Therapeutics Inc
    • Saniona AB
    • SciFluor Life Sciences LLC
    • Serina Therapeutics Inc
    • Shire Plc
    • SK Biopharmaceuticals Co Ltd
    • Suda Ltd
    • Sumitomo Dainippon Pharma Co Ltd
    • Takeda Pharmaceutical Company Ltd
    • Trillium Therapeutics Inc
    • Turing Pharmaceuticals AG
    • UCB SA
    • Ultragenyx Pharmaceutical Inc
    • Upsher-Smith Laboratories Inc
    • VistaGen Therapeutics Inc
    • Vitality Biopharma Inc
    • Xenon Pharmaceuticals Inc
    • XERIS Pharmaceuticals Inc
    • Zogenix Inc
    • Zynerba Pharmaceuticals Inc
  • Epilepsy - Drug Profiles
    • 2-DG - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADS-9000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADV-6208 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEOL-11114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alprazolam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMPX-0079 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANAVEX-273 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide for Dravet Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit miR-134 for Status Epilepticus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ataluren - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUC-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVL-5189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIS-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNP-TLE - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPS-015 SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brexanolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brivaracetam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BVA-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCG-63802 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cenobamate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CERC-611 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHEC-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clobazam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cosyntropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cosyntropin ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPP-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CUR-1916 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diazepam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diazepam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diazepam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • divalproex sodium ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DP-VPA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-2082 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-2730 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eslicarbazepine acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ethosuximide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fenfluramine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosphenytoin sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gaboxadol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ganaxolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLX-1112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GWP-42006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • histamine dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INV-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPRO-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JBPOS-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-40411813 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KM-113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KM-314 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lacosamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lacosamide ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lamotrigine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LAU-09021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levetiracetam ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LM-22A4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lorazepam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LSPGR-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-4121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-4122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-4123 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-4124 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-4125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-4126 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • magnesium valproate hydrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MB-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metformin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • midazolam hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • midazolam hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • midazolam hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • midazolam hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Activate Sodium Potassium ATPase for Congestive Heart Failure and Status Epilepticus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MRS-5474 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naluzotan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAX-8102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCT-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCT-10002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCT-10003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGT-168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NH-34 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRP-2945 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NST-0037 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NST-0076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORP-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • padsevonil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • perampanel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06372865 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propofol hemisuccinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • radiprodil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RL-81 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-324 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-689 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCT-66 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selurampanel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SER-228 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-0034 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGE-516 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGE-872 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKLN-09 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 3 for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 4 for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPC4 and TRPC5 for Cardiovascular Disease and Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules 1 for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules 2 for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules 3 for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules 4 for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Pain and Seizure Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Kv7.2 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dynamin for Epilepsy and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sulthiame - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-935 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Tardoxal - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TF-0081 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-4155 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • topiramate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TUR-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UX-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAD-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAD-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAL-0417 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0456810 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Z-944 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Epilepsy - Dormant Projects
  • Epilepsy - Discontinued Products
  • Epilepsy - Product Development Milestones
    • Featured News & Press Releases
      • Mar 08, 2017: OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder
      • Mar 01, 2017: Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
      • Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia
      • Feb 16, 2017: Knopp Biosciences Announces NIH Blueprint Grant Award
      • Feb 15, 2017: Insys Therapeutics Announces Use of Cannabidiol Oral Solution for Compassionate Use Studies in Patients Completing Long-Term Safety Study
      • Feb 14, 2017: Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model
      • Feb 13, 2017: MMJ PhytoTech Announces Phase 2 Clinical Trial For Treatment of Epilepsy Underway
      • Jan 30, 2017: Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome
      • Jan 23, 2017: Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
      • Jan 19, 2017: UCB files BRIVIACT (brivaracetam) CV in the U.S. as monotherapy treatment for adult epilepsy patients with partial-onset seizures
      • Jan 08, 2017: Adamas Pharmaceuticals Outlines Key Business Priorities for 2017, Provides Update on ADS-4101
      • Jan 06, 2017: Monosol Rx Successfully Completes Dose Proportionality Study Of Diazepam Buccal Soluble Film To Treat Acute Repetitive Seizures
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Epilepsy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Epilepsy - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by Advicenne SA, H1 2017
  • Epilepsy - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by Aequus Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by Alexza Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Epilepsy - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017
  • Epilepsy - Pipeline by Astellas Pharma Inc, H1 2017
  • Epilepsy - Pipeline by Bial - Portela & Ca SA, H1 2017
  • Epilepsy - Pipeline by BioCrea GmbH, H1 2017
  • Epilepsy - Pipeline by BioHealthonomics Inc, H1 2017
  • Epilepsy - Pipeline by Bionomics Ltd, H1 2017
  • Epilepsy - Pipeline by Biovista Inc, H1 2017
  • Epilepsy - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by Catalyst Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by Cerecor Inc, H1 2017
  • Epilepsy - Pipeline by D-Pharm Ltd, H1 2017
  • Epilepsy - Pipeline by Eisai Co Ltd, H1 2017
  • Epilepsy - Pipeline by Glialogix Inc, H1 2017
  • Epilepsy - Pipeline by Grifols SA, H1 2017
  • Epilepsy - Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Epilepsy - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
  • Epilepsy - Pipeline by INSYS Therapeutics Inc, H1 2017
  • Epilepsy - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by Iproteos SL, H1 2017
  • Epilepsy - Pipeline by Johnson & Johnson, H1 2017
  • Epilepsy - Pipeline by Knopp Biosciences LLC, H1 2017
  • Epilepsy - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Epilepsy - Pipeline by Lipicard Technologies Ltd, H1 2017
  • Epilepsy - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
  • Epilepsy - Pipeline by Marathon Pharmaceuticals LLC, H1 2017
  • Epilepsy - Pipeline by Marinus Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by Medicure Inc, H1 2017
  • Epilepsy - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by Monosol Rx LLC, H1 2017
  • Epilepsy - Pipeline by Neurelis Inc, H1 2017
  • Epilepsy - Pipeline by Neurocrine Biosciences Inc, H1 2017
  • Epilepsy - Pipeline by NeuroCycle Therapeutics GmbH, H1 2017
  • Epilepsy - Pipeline by Neuron Biopharma SA, H1 2017
  • Epilepsy - Pipeline by Novartis AG, H1 2017
  • Epilepsy - Pipeline by OPKO Health Inc, H1 2017
  • Epilepsy - Pipeline by Ovid Therapeutics Inc, H1 2017
  • Epilepsy - Pipeline by Pfizer Inc, H1 2017
  • Epilepsy - Pipeline by PharmatrophiX Inc, H1 2017
  • Epilepsy - Pipeline by Promius Pharma LLC, H1 2017
  • Epilepsy - Pipeline by Proximagen Ltd, H1 2017
  • Epilepsy - Pipeline by PTC Therapeutics Inc, H1 2017
  • Epilepsy - Pipeline by Retrophin Inc, H1 2017
  • Epilepsy - Pipeline by Sage Therapeutics Inc, H1 2017
  • Epilepsy - Pipeline by Saniona AB, H1 2017
  • Epilepsy - Pipeline by SciFluor Life Sciences LLC, H1 2017
  • Epilepsy - Pipeline by Serina Therapeutics Inc, H1 2017
  • Epilepsy - Pipeline by Shire Plc, H1 2017
  • Epilepsy - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
  • Epilepsy - Pipeline by Suda Ltd, H1 2017
  • Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Epilepsy - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Epilepsy - Pipeline by Trillium Therapeutics Inc, H1 2017
  • Epilepsy - Pipeline by Turing Pharmaceuticals AG, H1 2017
  • Epilepsy - Pipeline by UCB SA, H1 2017
  • Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2017
  • Epilepsy - Pipeline by Upsher-Smith Laboratories Inc, H1 2017
  • Epilepsy - Pipeline by VistaGen Therapeutics Inc, H1 2017
  • Epilepsy - Pipeline by Vitality Biopharma Inc, H1 2017
  • Epilepsy - Pipeline by Xenon Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by XERIS Pharmaceuticals Inc, H1 2017
  • Epilepsy - Pipeline by Zogenix Inc, H1 2017
  • Epilepsy - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
  • Epilepsy - Dormant Projects, H1 2017
  • Epilepsy - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Epilepsy - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Epilepsy - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Epilepsy - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Epilepsy - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Epilepsy - Discontinued Products, H1 2017
  • Epilepsy - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Epilepsy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top